Category: 428855-17-8

On October 1, 2019, Li, Xue; Zhu, Pei; Xiang, Chaoyu published a patent.Name: 1-[(Dibenzylamino)methyl]cyclopropanol The title of the patent was Inkjet printing ink. And the patent contained the following:

Title ink comprises 0.1-20.0% of inorganic nanomaterials (oleylamine-stabilized red CdSe/ZnS quantum dots) and 80.0-99.9% of solvent (tetradecane and (R)-2,2-dimethyl-1,3-dioxolan-4-propanol), wherein the solvent comprises at least one cyclic alc. organic solvent. The experimental process involved the reaction of 1-[(Dibenzylamino)methyl]cyclopropanol(cas: 428855-17-8).Name: 1-[(Dibenzylamino)methyl]cyclopropanol

The Article related to quantum dot inkjet printing ink, Coatings, Inks, and Related Products: Inks and other aspects.Name: 1-[(Dibenzylamino)methyl]cyclopropanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On May 14, 2019, Sun, Changan; Gao, Peng; Liu, Lei; Bao, Rudi published a patent.Recommanded Product: 1-[(Dibenzylamino)methyl]cyclopropanol The title of the patent was Pharmaceutical composition containing fibroblast growth factor receptor 4 (FGFR4) inhibitor. And the patent contained the following:

The invention relates to a pharmaceutical composition containing a fibroblast growth factor receptor 4 (FGFR4) inhibitor, and in particular to a pharmaceutical composition containing a FGFR4 inhibitor having structure of formula (I). The pharmaceutical composition has high inhibiting effect on activity of FGFR4 kinase, and can be widely applied to preparation of pharmaceuticals for treating cancers, especially liver cancer, gastric cancer, prostatic cancer, skin cancer, ovarian cancer, lung cancer, breast cancer, colon cancer, pancreatic cancer, esophageal cancer, glioma or rhabdomyosarcoma. The experimental process involved the reaction of 1-[(Dibenzylamino)methyl]cyclopropanol(cas: 428855-17-8).Recommanded Product: 1-[(Dibenzylamino)methyl]cyclopropanol

The Article related to fibroblast growth factor receptor inhibitor antineoplastic cancer, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 1-[(Dibenzylamino)methyl]cyclopropanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On October 22, 2015, Hirayama, Takaharu; Fujimoto, Jun; Cary, Douglas Robert; Okaniwa, Masanori; Hirata, Yasuhiro published a patent.HPLC of Formula: 428855-17-8 The title of the patent was Preparation of heterocyclic compounds as cyclin-dependent protein kinase inhibitors for prophylactic and therapeutic treatment of cancer. And the patent contained the following:

The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula I [R1-R3, R5a, R5b, R7, R8 = H, substituent; R4 = (un)substituted heteroaryl; R5a and R5b may be bonded to form double bond or C3-4 cycloalkyl; R7 and R8 may be bonded to form N-containing heterocyclyl] or a salt thereof. Thus, (2E)-N-[4-[2-(1,3,4-oxadiazol-2-yl)ethyl]phenyl]-3-[4-(2-thienyl)pyridin-3-yl]acrylamide (preparation given) inhibited CDK8 and CDK19 activity with inhibitory rates of 101 and 100%, resp. at 1 μM and inhibited RPMI8226 cell proliferation with inhibitory rate of 59% at 1 μM. The experimental process involved the reaction of 1-[(Dibenzylamino)methyl]cyclopropanol(cas: 428855-17-8).HPLC of Formula: 428855-17-8

The Article related to preparation heterocycle cyclin dependent protein kinase inhibitor antitumor, pyridine preparation cdk8 cdk19 inhibitor antitumor, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.HPLC of Formula: 428855-17-8

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On February 12, 2015, Aida, Jumpei; Yoshitomi, Yayoi; Hitomi, Yuko; Noguchi, Naoyoshi; Hirata, Yasuhiro; Furukawa, Hideki; Shibuya, Akito; Watanabe, Koji; Miyamoto, Yasufumi; Okawa, Tomohiro; Takakura, Nobuyuki; Miwatashi, Seiji published a patent.Name: 1-[(Dibenzylamino)methyl]cyclopropanol The title of the patent was Preparation of heterocyclic compounds as GPR40 agonists, regulating method for GPR40 receptors, and preventive and therapeutic methods for diabetes. And the patent contained the following:

The heterocyclic compounds or their salts are represented by formula I [A = (un)substituted aromatic ring; B = (un)substituted 4 to 6-membered N-containing alicyclic ring; X = N, CH; R1, R2 = H, substituent; R1 and R2 may form 3 to 10-membered ring with neighbored N atom; R3, R4 = H, halo, C1-6 alkyl; R5, R7-R9 = H, halo, C1-6 alkyl, C1-6 alkoxy; R6 = halo, (un)substituted C1-6 alkyl, C1-6 alkoxy, or C3-10 cycloalkyl; R6 and R7 may form 3 to 10-membered ring with neighbored C atom]. Thus, reacting 2-fluoro-4-methoxy-N-methyl-N-(2-methylpropyl)benzamide (preparation given) with piperidine-4-methanol, etherifying with Me 3-cyclopropyl-3-(3-hydroxyphenyl)propanoate, and hydrolyzing with 1 N NaOH, gave 3-cyclopropyl-3-[3-[[1-[5-methoxy-2-[methyl(2-methylpropyl)carbamoyl]-phenyl]piperidin-4-yl]methoxy]phenyl]propanoic acid with G protein-coupled receptor 40 (GPR40) agonist activity 97%. Formulations containing I are given. The experimental process involved the reaction of 1-[(Dibenzylamino)methyl]cyclopropanol(cas: 428855-17-8).Name: 1-[(Dibenzylamino)methyl]cyclopropanol

The Article related to gpr40 regulation agonist preparation glp1 diabetes therapeutic agent, Heterocyclic Compounds (One Hetero Atom): Other 6-Membered Rings and other aspects.Name: 1-[(Dibenzylamino)methyl]cyclopropanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On February 22, 2017, Zhao, Fulu; Wang, Qi; Wang, Yinhu; Li, Sen; Wang, Lichun; Wang, Jingyi published a patent.Related Products of 428855-17-8 The title of the patent was Intermediate compound of LB80380 drug and preparation method and application thereof. And the patent contained the following:

The invention provides an intermediate compound of LB80380 represented by formula I, wherein R1, R2, R3 and R4 are independently selected from linear or branched-chain alkyl, benzyl substituted with 1-5 R5 groups and R5CO, and are the same or different, and R5 is selected from H, substituted or unsubstituted C1-C4 alkoxy, C3-C7 alkenyl alkoxy and substituted or unsubstituted benzyloxy. The invention also provides a method for preparing the compound and application of the compound When the compound was used for preparing compound 3-[({1-[(2-amino-9H-purin-9-yl) methyl]cyclopropyl}oxy) methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-3λ-phosphanonan-yl-pivalate;, the reaction route has easily available low-cost raw materials and intermediate, low cost and high safety, and is suitable for industrial production The experimental process involved the reaction of 1-[(Dibenzylamino)methyl]cyclopropanol(cas: 428855-17-8).Related Products of 428855-17-8

The Article related to lb80380 drug intermediate preparation, Organometallic and Organometalloidal Compounds: Phosphorus Compounds and other aspects.Related Products of 428855-17-8

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On March 12, 2020, Becker, Christopher; Li, Xiaolin; Lu, Peichao; Rajapaksa, Naomi Samadara; Tully, David Charles; Wang, Xiaojing Michael; Zhao, Qian published a patent.Recommanded Product: 1-[(Dibenzylamino)methyl]cyclopropanol The title of the patent was Preparation of pyridopyrazinedione compounds as antiviral agents for treating particularly herpes viruses. And the patent contained the following:

The invention is related to the preparation of compounds I [Cy = (un)substituted Ph, pyridinyl, pyrimidinyl, or a 5-8 membered cycloalkyl; R1, R2 = independently H, C1-3 alkyl; or R1CR2 = 3-6 membered cycloalkyl ring; R3 = 0-2 optional substituents on the ring to which -L-W is directly attached; R4 = H, halo, C1-3 alkyl; R5 = H, halo, CN, C1-3 alkoxy, etc.; L = C1-C4 straight chain or branched alkylene linker, or L = C1-C4 straight chain or branched alkylene linker or a bond when W is an optionally substituted ring; W = H, OH, an optionally substituted ring selected from 3-6 membered cycloalkyl, Ph, 5-6-membered heterocyclyl containing one or two N, O or S heteroatoms as ring members, and 5-membered heteroaryl containing up to 4 heteroatoms selected from N, O and S as ring members that is optionally fused to Ph, etc.; Y = (CH2)0-2] their pharmaceutically acceptable salts, to pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses. Thus, II (m.p. = 186°) was prepared by reaction of Bu 1,6-dioxo-2,3,4,6-tetrahydro-1H-pyrido[1,2-a]pyrazine-7-carboxylate (preparation given) with [1-(cyclopropylsulfonyl)cyclopropyl]methyl Methanesulfonate (preparation given) in DMF in the presence of NaH, acidulation of III•Na, activation of the acid III with oxalyl chloride, amidation with 4-(aminomethyl)benzonitrile hydrochloride. The exemplified compounds of the invention were studied in an CMV polymerase, CMV-luciferase and HSV polymerase assays (some data given). The activity of I against human herpes viruses CMV HSV-1, VZV and EBV was evaluated [Ec50 values of 24(±7) nM, 32(±12), 20(±8) and 12(±), resp]. The experimental process involved the reaction of 1-[(Dibenzylamino)methyl]cyclopropanol(cas: 428855-17-8).Recommanded Product: 1-[(Dibenzylamino)methyl]cyclopropanol

The Article related to pyridopyrazinedione preparation herpes antiviral, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Recommanded Product: 1-[(Dibenzylamino)methyl]cyclopropanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On November 23, 2017, Gao, Peng; Xiu, Wenhua; Wang, Shaobao; Liu, Lei; Bao, Rudi published a patent.Category: alcohols-buliding-blocks The title of the patent was FGFR4 inhibitor, preparation method and applications. And the patent contained the following:

The invention disclosed a kind of FGFR4 inhibitor, its preparation method and application. The claimed FGFR4 inhibitor is shown in structure I (X1 = -(CR3R4)m1-; X2 = -(CR5R6)m2-; X3 = -(CR7R8)m3-; Y = O or S; Z = NX4, O or S; X4 = H, C1-8 alkyl or haloalkyl, C3-8 cycloalkyl; R = H, halo, hydroxy, mercapto, cyano, etc.; R1 = H, halo, hydroxy, mercapto, cyano, nitro, C3-8 cycloalkyl, heterocyclo, etc.; R2 = halo, hydroxy, mercapto, cyano, nitro, etc.; R3,R4,R5,R6,R7,R8 = H, D, halo, C1-8 alkyl, C2-8 alkenyl, alkynyl, etc.). The claimed compound is prepared via multiple steps (procedure given). The prepared compound have a very-strong inhibition effect on the activity of FGFR4 kinase, has very-high selectivity, can be widely used in the preparation of drugs for treating cancers, specially liver cancer, stomach cancer, prostate cancer, skin cancer, ovarian cancer, lung cancer, breast cancer or colon cancer, and can be developed into a rnew-generation FGFR4 inhibitor drug. The experimental process involved the reaction of 1-[(Dibenzylamino)methyl]cyclopropanol(cas: 428855-17-8).Category: alcohols-buliding-blocks

The Article related to fgfr4 inhibitor preparation antitumor agent, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Category: alcohols-buliding-blocks

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On September 30, 2001, Lysenko, I. L.; Kulinkovich, O. G. published an article.Recommanded Product: 1-[(Dibenzylamino)methyl]cyclopropanol The title of the article was A convenient procedure for preparation of 1-(1-aminoalkyl)-1-cyclopropanols from N-benzyl α-amino acid esters. And the article contained the following:

The reaction of N-benzyl α-amino acid Et esters, e.g. I, with ethylmagnesium bromide in the presence of a catalytic amount of titanium tetraisopropoxide leads to formation of the corresponding 1-aminoalkyl-1-cyclopropanols, e.g. II, in high yields. Hydrogenation of the latter over palladium catalyst ensures selective removal of one or two protecting benzyl groups from the nitrogen atom. The experimental process involved the reaction of 1-[(Dibenzylamino)methyl]cyclopropanol(cas: 428855-17-8).Recommanded Product: 1-[(Dibenzylamino)methyl]cyclopropanol

The Article related to aminoalkyl cyclopropanol asym synthesis benzyl amino acid ester cyclopropanation, aminoalkylcyclopropanol asym synthesis benzyl amino acid ester cyclopropanation, deprotection dibenzyl aminoalkyl cyclopropanol hydrogenation and other aspects.Recommanded Product: 1-[(Dibenzylamino)methyl]cyclopropanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts